BioCentury
ARTICLE | Product Development

Self-driving CARs

Why Pfizer and other large companies think CAR T technology needs its independence

April 13, 2018 9:53 PM UTC

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology requires a level of autonomy that is unavailable within the traditional biopharma operating model.

Each has chosen to house its CAR T cell pipelines in an entity that operates independently of the rest of its pharmaceutical operations...